Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
04 mars 2024 08h00 HE
|
Aclarion, Inc.
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
05 févr. 2024 08h00 HE
|
Aclarion, Inc.
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
17 janv. 2024 08h00 HE
|
Aclarion, Inc.
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds...
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
08 janv. 2024 08h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented...
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
27 nov. 2023 08h00 HE
|
Aclarion, Inc.
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel...
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
08 nov. 2023 08h00 HE
|
Aclarion, Inc.
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
06 nov. 2023 08h00 HE
|
Aclarion, Inc.
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
25 oct. 2023 08h30 HE
|
Aclarion, Inc.
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
23 oct. 2023 07h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to...
Aclarion Provides Updated Investor Presentation and Corporate Update
02 oct. 2023 08h00 HE
|
Aclarion, Inc.
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and...